The global Poly-Myalgia Rheumatica Treatment market was valued at US$ 193 million in 2023 and is anticipated to reach US$ 287.7 million by 2030, witnessing a CAGR of 5.9% during the forecast period 2024-2030.

Poly-Myalgia Rheumatica Treatment Market

Rheumatic polymyalgia (PMR) is a painful disease unrelated to other definitely diagnosed rheumatic diseases, infections and tumors. It is common in the elderly, accompanied by rapid erythrocyte sedimentation rate. PMR is a clinical syndrome characterized by limb and proximal trunk muscle pain, which is sensitive to low-dose hormone therapy. It often shows pain and stiffness in 2 or more parts of the neck, scapular band and pelvic band muscles, lasting for 30 minutes or more, not less than 1 month, and older than 50 years.

报错

笔记

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Poly-Myalgia Rheumatica Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Poly-Myalgia Rheumatica Treatment.

Report Scope

The Poly-Myalgia Rheumatica Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Poly-Myalgia Rheumatica Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Poly-Myalgia Rheumatica Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Poly-Myalgia Rheumatica Treatment Market Report

Report Metric	Details
Report Name	Poly-Myalgia Rheumatica Treatment Market
Accounted market size in 2023	US$ 193 million
Forecasted market size in 2030	US$ 287.7 million
CAGR	5.9%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Glucocorticoid NSAIDs
Segment by Application	Hospital Specialist Clinic
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Mylan N.V, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GSK plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd, Merck & Co., Inc, Lilly, Amgen Inc, PuraCap® Pharmaceutical LLC, Glenmark Pharmaceuticals Limited
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Poly-Myalgia Rheumatica Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Poly-Myalgia Rheumatica Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Poly-Myalgia Rheumatica Treatment Market growing?

Ans: The Poly-Myalgia Rheumatica Treatment Market witnessing a CAGR of 5.9% during the forecast period 2024-2030.

What is the Poly-Myalgia Rheumatica Treatment Market size in 2030?

Ans: The Poly-Myalgia Rheumatica Treatment Market size in 2030 will be US$ 287.7 million.

Who are the main players in the Poly-Myalgia Rheumatica Treatment Market report?

Ans: The main players in the Poly-Myalgia Rheumatica Treatment Market are Mylan N.V, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GSK plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd, Merck & Co., Inc, Lilly, Amgen Inc, PuraCap® Pharmaceutical LLC, Glenmark Pharmaceuticals Limited

What are the Application segmentation covered in the Poly-Myalgia Rheumatica Treatment Market report?

Ans: The Applications covered in the Poly-Myalgia Rheumatica Treatment Market report are Hospital, Specialist Clinic

What are the Type segmentation covered in the Poly-Myalgia Rheumatica Treatment Market report?

Ans: The Types covered in the Poly-Myalgia Rheumatica Treatment Market report are Glucocorticoid, NSAIDs

1 Poly-Myalgia Rheumatica Treatment Market Overview

1.1 Product Overview and Scope of Poly-Myalgia Rheumatica Treatment

1.2 Poly-Myalgia Rheumatica Treatment Segment by Type

1.2.1 Global Poly-Myalgia Rheumatica Treatment Market Value Comparison by Type (2024-2030)

1.2.2 Glucocorticoid

1.2.3 NSAIDs

1.3 Poly-Myalgia Rheumatica Treatment Segment by Application

1.3.1 Global Poly-Myalgia Rheumatica Treatment Market Value by Application: (2024-2030)

1.3.2 Hospital

1.3.3 Specialist Clinic

1.4 Global Poly-Myalgia Rheumatica Treatment Market Size Estimates and Forecasts

1.4.1 Global Poly-Myalgia Rheumatica Treatment Revenue 2019-2030

1.4.2 Global Poly-Myalgia Rheumatica Treatment Sales 2019-2030

1.4.3 Global Poly-Myalgia Rheumatica Treatment Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Poly-Myalgia Rheumatica Treatment Market Competition by Manufacturers

2.1 Global Poly-Myalgia Rheumatica Treatment Sales Market Share by Manufacturers (2019-2024)

2.2 Global Poly-Myalgia Rheumatica Treatment Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Poly-Myalgia Rheumatica Treatment Average Price by Manufacturers (2019-2024)

2.4 Global Poly-Myalgia Rheumatica Treatment Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Poly-Myalgia Rheumatica Treatment, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Poly-Myalgia Rheumatica Treatment, Product Type & Application

2.7 Poly-Myalgia Rheumatica Treatment Market Competitive Situation and Trends

2.7.1 Poly-Myalgia Rheumatica Treatment Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Poly-Myalgia Rheumatica Treatment Players Market Share by Revenue

2.7.3 Global Poly-Myalgia Rheumatica Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Poly-Myalgia Rheumatica Treatment Retrospective Market Scenario by Region

3.1 Global Poly-Myalgia Rheumatica Treatment Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Poly-Myalgia Rheumatica Treatment Global Poly-Myalgia Rheumatica Treatment Sales by Region: 2019-2030

3.2.1 Global Poly-Myalgia Rheumatica Treatment Sales by Region: 2019-2024

3.2.2 Global Poly-Myalgia Rheumatica Treatment Sales by Region: 2025-2030

3.3 Global Poly-Myalgia Rheumatica Treatment Global Poly-Myalgia Rheumatica Treatment Revenue by Region: 2019-2030

3.3.1 Global Poly-Myalgia Rheumatica Treatment Revenue by Region: 2019-2024

3.3.2 Global Poly-Myalgia Rheumatica Treatment Revenue by Region: 2025-2030

3.4 North America Poly-Myalgia Rheumatica Treatment Market Facts & Figures by Country

3.4.1 North America Poly-Myalgia Rheumatica Treatment Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Poly-Myalgia Rheumatica Treatment Sales by Country (2019-2030)

3.4.3 North America Poly-Myalgia Rheumatica Treatment Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Poly-Myalgia Rheumatica Treatment Market Facts & Figures by Country

3.5.1 Europe Poly-Myalgia Rheumatica Treatment Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Poly-Myalgia Rheumatica Treatment Sales by Country (2019-2030)

3.5.3 Europe Poly-Myalgia Rheumatica Treatment Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Poly-Myalgia Rheumatica Treatment Market Facts & Figures by Country

3.6.1 Asia Pacific Poly-Myalgia Rheumatica Treatment Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Poly-Myalgia Rheumatica Treatment Sales by Country (2019-2030)

3.6.3 Asia Pacific Poly-Myalgia Rheumatica Treatment Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Poly-Myalgia Rheumatica Treatment Market Facts & Figures by Country

3.7.1 Latin America Poly-Myalgia Rheumatica Treatment Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Poly-Myalgia Rheumatica Treatment Sales by Country (2019-2030)

3.7.3 Latin America Poly-Myalgia Rheumatica Treatment Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Poly-Myalgia Rheumatica Treatment Market Facts & Figures by Country

3.8.1 Middle East and Africa Poly-Myalgia Rheumatica Treatment Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Poly-Myalgia Rheumatica Treatment Sales by Country (2019-2030)

3.8.3 Middle East and Africa Poly-Myalgia Rheumatica Treatment Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Poly-Myalgia Rheumatica Treatment Sales by Type (2019-2030)

4.1.1 Global Poly-Myalgia Rheumatica Treatment Sales by Type (2019-2024)

4.1.2 Global Poly-Myalgia Rheumatica Treatment Sales by Type (2025-2030)

4.1.3 Global Poly-Myalgia Rheumatica Treatment Sales Market Share by Type (2019-2030)

4.2 Global Poly-Myalgia Rheumatica Treatment Revenue by Type (2019-2030)

4.2.1 Global Poly-Myalgia Rheumatica Treatment Revenue by Type (2019-2024)

4.2.2 Global Poly-Myalgia Rheumatica Treatment Revenue by Type (2025-2030)

4.2.3 Global Poly-Myalgia Rheumatica Treatment Revenue Market Share by Type (2019-2030)

4.3 Global Poly-Myalgia Rheumatica Treatment Price by Type (2019-2030)

5 Segment by Application

5.1 Global Poly-Myalgia Rheumatica Treatment Sales by Application (2019-2030)

5.1.1 Global Poly-Myalgia Rheumatica Treatment Sales by Application (2019-2024)

5.1.2 Global Poly-Myalgia Rheumatica Treatment Sales by Application (2025-2030)

5.1.3 Global Poly-Myalgia Rheumatica Treatment Sales Market Share by Application (2019-2030)

5.2 Global Poly-Myalgia Rheumatica Treatment Revenue by Application (2019-2030)

5.2.1 Global Poly-Myalgia Rheumatica Treatment Revenue by Application (2019-2024)

5.2.2 Global Poly-Myalgia Rheumatica Treatment Revenue by Application (2025-2030)

5.2.3 Global Poly-Myalgia Rheumatica Treatment Revenue Market Share by Application (2019-2030)

5.3 Global Poly-Myalgia Rheumatica Treatment Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Mylan N.V

6.1.1 Mylan N.V Corporation Information

6.1.2 Mylan N.V Description and Business Overview

6.1.3 Mylan N.V Poly-Myalgia Rheumatica Treatment Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Mylan N.V Poly-Myalgia Rheumatica Treatment Product Portfolio

6.1.5 Mylan N.V Recent Developments/Updates

6.2 Teva Pharmaceutical Industries Ltd

6.2.1 Teva Pharmaceutical Industries Ltd Corporation Information

6.2.2 Teva Pharmaceutical Industries Ltd Description and Business Overview

6.2.3 Teva Pharmaceutical Industries Ltd Poly-Myalgia Rheumatica Treatment Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Teva Pharmaceutical Industries Ltd Poly-Myalgia Rheumatica Treatment Product Portfolio

6.2.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates

6.3 Sanofi

6.3.1 Sanofi Corporation Information

6.3.2 Sanofi Description and Business Overview

6.3.3 Sanofi Poly-Myalgia Rheumatica Treatment Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Sanofi Poly-Myalgia Rheumatica Treatment Product Portfolio

6.3.5 Sanofi Recent Developments/Updates

6.4 Pfizer Inc

6.4.1 Pfizer Inc Corporation Information

6.4.2 Pfizer Inc Description and Business Overview

6.4.3 Pfizer Inc Poly-Myalgia Rheumatica Treatment Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Pfizer Inc Poly-Myalgia Rheumatica Treatment Product Portfolio

6.4.5 Pfizer Inc Recent Developments/Updates

6.5 GSK plc

6.5.1 GSK plc Corporation Information

6.5.2 GSK plc Description and Business Overview

6.5.3 GSK plc Poly-Myalgia Rheumatica Treatment Sales, Revenue and Gross Margin (2019-2024)

6.5.4 GSK plc Poly-Myalgia Rheumatica Treatment Product Portfolio

6.5.5 GSK plc Recent Developments/Updates

6.6 Novartis AG

6.6.1 Novartis AG Corporation Information

6.6.2 Novartis AG Description and Business Overview

6.6.3 Novartis AG Poly-Myalgia Rheumatica Treatment Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Novartis AG Poly-Myalgia Rheumatica Treatment Product Portfolio

6.6.5 Novartis AG Recent Developments/Updates

6.7 AstraZeneca

6.6.1 AstraZeneca Corporation Information

6.6.2 AstraZeneca Description and Business Overview

6.6.3 AstraZeneca Poly-Myalgia Rheumatica Treatment Sales, Revenue and Gross Margin (2019-2024)

6.4.4 AstraZeneca Poly-Myalgia Rheumatica Treatment Product Portfolio

6.7.5 AstraZeneca Recent Developments/Updates

6.8 Johnson & Johnson Private Limited

6.8.1 Johnson & Johnson Private Limited Corporation Information

6.8.2 Johnson & Johnson Private Limited Description and Business Overview

6.8.3 Johnson & Johnson Private Limited Poly-Myalgia Rheumatica Treatment Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Johnson & Johnson Private Limited Poly-Myalgia Rheumatica Treatment Product Portfolio

6.8.5 Johnson & Johnson Private Limited Recent Developments/Updates

6.9 Sun Pharmaceutical Industries Ltd

6.9.1 Sun Pharmaceutical Industries Ltd Corporation Information

6.9.2 Sun Pharmaceutical Industries Ltd Description and Business Overview

6.9.3 Sun Pharmaceutical Industries Ltd Poly-Myalgia Rheumatica Treatment Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Sun Pharmaceutical Industries Ltd Poly-Myalgia Rheumatica Treatment Product Portfolio

6.9.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates

6.10 Merck & Co., Inc

6.10.1 Merck & Co., Inc Corporation Information

6.10.2 Merck & Co., Inc Description and Business Overview

6.10.3 Merck & Co., Inc Poly-Myalgia Rheumatica Treatment Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Merck & Co., Inc Poly-Myalgia Rheumatica Treatment Product Portfolio

6.10.5 Merck & Co., Inc Recent Developments/Updates

6.11 Lilly

6.11.1 Lilly Corporation Information

6.11.2 Lilly Poly-Myalgia Rheumatica Treatment Description and Business Overview

6.11.3 Lilly Poly-Myalgia Rheumatica Treatment Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Lilly Poly-Myalgia Rheumatica Treatment Product Portfolio

6.11.5 Lilly Recent Developments/Updates

6.12 Amgen Inc

6.12.1 Amgen Inc Corporation Information

6.12.2 Amgen Inc Poly-Myalgia Rheumatica Treatment Description and Business Overview

6.12.3 Amgen Inc Poly-Myalgia Rheumatica Treatment Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Amgen Inc Poly-Myalgia Rheumatica Treatment Product Portfolio

6.12.5 Amgen Inc Recent Developments/Updates

6.13 PuraCap® Pharmaceutical LLC

6.13.1 PuraCap® Pharmaceutical LLC Corporation Information

6.13.2 PuraCap® Pharmaceutical LLC Poly-Myalgia Rheumatica Treatment Description and Business Overview

6.13.3 PuraCap® Pharmaceutical LLC Poly-Myalgia Rheumatica Treatment Sales, Revenue and Gross Margin (2019-2024)

6.13.4 PuraCap® Pharmaceutical LLC Poly-Myalgia Rheumatica Treatment Product Portfolio

6.13.5 PuraCap® Pharmaceutical LLC Recent Developments/Updates

6.14 Glenmark Pharmaceuticals Limited

6.14.1 Glenmark Pharmaceuticals Limited Corporation Information

6.14.2 Glenmark Pharmaceuticals Limited Poly-Myalgia Rheumatica Treatment Description and Business Overview

6.14.3 Glenmark Pharmaceuticals Limited Poly-Myalgia Rheumatica Treatment Sales, Revenue and Gross Margin (2019-2024)

6.14.4 Glenmark Pharmaceuticals Limited Poly-Myalgia Rheumatica Treatment Product Portfolio

6.14.5 Glenmark Pharmaceuticals Limited Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Poly-Myalgia Rheumatica Treatment Industry Chain Analysis

7.2 Poly-Myalgia Rheumatica Treatment Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Poly-Myalgia Rheumatica Treatment Production Mode & Process

7.4 Poly-Myalgia Rheumatica Treatment Sales and Marketing

7.4.1 Poly-Myalgia Rheumatica Treatment Sales Channels

7.4.2 Poly-Myalgia Rheumatica Treatment Distributors

7.5 Poly-Myalgia Rheumatica Treatment Customers

8 Poly-Myalgia Rheumatica Treatment Market Dynamics

8.1 Poly-Myalgia Rheumatica Treatment Industry Trends

8.2 Poly-Myalgia Rheumatica Treatment Market Drivers

8.3 Poly-Myalgia Rheumatica Treatment Market Challenges

8.4 Poly-Myalgia Rheumatica Treatment Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Mylan N.V.

Teva Pharmaceutical Industries Ltd

Johnson & Johnson Private Limited

Sun Pharmaceutical Industries Ltd.

Merck& Co. Inc

Lilly

Amgen Inc

Glenmark Pharmaceuticals Limited

PuraCap® Pharmaceutical LLC

List of Tables

Table 1. Global Poly-Myalgia Rheumatica Treatment Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Poly-Myalgia Rheumatica Treatment Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Poly-Myalgia Rheumatica Treatment Market Competitive Situation by Manufacturers in 2023

Table 4. Global Poly-Myalgia Rheumatica Treatment Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Poly-Myalgia Rheumatica Treatment Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Poly-Myalgia Rheumatica Treatment Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Poly-Myalgia Rheumatica Treatment Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Poly-Myalgia Rheumatica Treatment Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Poly-Myalgia Rheumatica Treatment, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Poly-Myalgia Rheumatica Treatment, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Poly-Myalgia Rheumatica Treatment, Product Type & Application

Table 12. Global Key Manufacturers of Poly-Myalgia Rheumatica Treatment, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Poly-Myalgia Rheumatica Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Poly-Myalgia Rheumatica Treatment as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Poly-Myalgia Rheumatica Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Poly-Myalgia Rheumatica Treatment Sales by Region (2019-2024) & (K Units)

Table 18. Global Poly-Myalgia Rheumatica Treatment Sales Market Share by Region (2019-2024)

Table 19. Global Poly-Myalgia Rheumatica Treatment Sales by Region (2025-2030) & (K Units)

Table 20. Global Poly-Myalgia Rheumatica Treatment Sales Market Share by Region (2025-2030)

Table 21. Global Poly-Myalgia Rheumatica Treatment Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Poly-Myalgia Rheumatica Treatment Revenue Market Share by Region (2019-2024)

Table 23. Global Poly-Myalgia Rheumatica Treatment Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Poly-Myalgia Rheumatica Treatment Revenue Market Share by Region (2025-2030)

Table 25. North America Poly-Myalgia Rheumatica Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Poly-Myalgia Rheumatica Treatment Sales by Country (2019-2024) & (K Units)

Table 27. North America Poly-Myalgia Rheumatica Treatment Sales by Country (2025-2030) & (K Units)

Table 28. North America Poly-Myalgia Rheumatica Treatment Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Poly-Myalgia Rheumatica Treatment Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Poly-Myalgia Rheumatica Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Poly-Myalgia Rheumatica Treatment Sales by Country (2019-2024) & (K Units)

Table 32. Europe Poly-Myalgia Rheumatica Treatment Sales by Country (2025-2030) & (K Units)

Table 33. Europe Poly-Myalgia Rheumatica Treatment Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Poly-Myalgia Rheumatica Treatment Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Poly-Myalgia Rheumatica Treatment Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Poly-Myalgia Rheumatica Treatment Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Poly-Myalgia Rheumatica Treatment Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Poly-Myalgia Rheumatica Treatment Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Poly-Myalgia Rheumatica Treatment Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Poly-Myalgia Rheumatica Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Poly-Myalgia Rheumatica Treatment Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Poly-Myalgia Rheumatica Treatment Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Poly-Myalgia Rheumatica Treatment Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Poly-Myalgia Rheumatica Treatment Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Poly-Myalgia Rheumatica Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Poly-Myalgia Rheumatica Treatment Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Poly-Myalgia Rheumatica Treatment Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Poly-Myalgia Rheumatica Treatment Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Poly-Myalgia Rheumatica Treatment Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Poly-Myalgia Rheumatica Treatment Sales (K Units) by Type (2019-2024)

Table 51. Global Poly-Myalgia Rheumatica Treatment Sales (K Units) by Type (2025-2030)

Table 52. Global Poly-Myalgia Rheumatica Treatment Sales Market Share by Type (2019-2024)

Table 53. Global Poly-Myalgia Rheumatica Treatment Sales Market Share by Type (2025-2030)

Table 54. Global Poly-Myalgia Rheumatica Treatment Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Poly-Myalgia Rheumatica Treatment Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Poly-Myalgia Rheumatica Treatment Revenue Market Share by Type (2019-2024)

Table 57. Global Poly-Myalgia Rheumatica Treatment Revenue Market Share by Type (2025-2030)

Table 58. Global Poly-Myalgia Rheumatica Treatment Price (US$/Unit) by Type (2019-2024)

Table 59. Global Poly-Myalgia Rheumatica Treatment Price (US$/Unit) by Type (2025-2030)

Table 60. Global Poly-Myalgia Rheumatica Treatment Sales (K Units) by Application (2019-2024)

Table 61. Global Poly-Myalgia Rheumatica Treatment Sales (K Units) by Application (2025-2030)

Table 62. Global Poly-Myalgia Rheumatica Treatment Sales Market Share by Application (2019-2024)

Table 63. Global Poly-Myalgia Rheumatica Treatment Sales Market Share by Application (2025-2030)

Table 64. Global Poly-Myalgia Rheumatica Treatment Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Poly-Myalgia Rheumatica Treatment Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Poly-Myalgia Rheumatica Treatment Revenue Market Share by Application (2019-2024)

Table 67. Global Poly-Myalgia Rheumatica Treatment Revenue Market Share by Application (2025-2030)

Table 68. Global Poly-Myalgia Rheumatica Treatment Price (US$/Unit) by Application (2019-2024)

Table 69. Global Poly-Myalgia Rheumatica Treatment Price (US$/Unit) by Application (2025-2030)

Table 70. Mylan N.V Corporation Information

Table 71. Mylan N.V Description and Business Overview

Table 72. Mylan N.V Poly-Myalgia Rheumatica Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Mylan N.V Poly-Myalgia Rheumatica Treatment Product

Table 74. Mylan N.V Recent Developments/Updates

Table 75. Teva Pharmaceutical Industries Ltd Corporation Information

Table 76. Teva Pharmaceutical Industries Ltd Description and Business Overview

Table 77. Teva Pharmaceutical Industries Ltd Poly-Myalgia Rheumatica Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Teva Pharmaceutical Industries Ltd Poly-Myalgia Rheumatica Treatment Product

Table 79. Teva Pharmaceutical Industries Ltd Recent Developments/Updates

Table 80. Sanofi Corporation Information

Table 81. Sanofi Description and Business Overview

Table 82. Sanofi Poly-Myalgia Rheumatica Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Sanofi Poly-Myalgia Rheumatica Treatment Product

Table 84. Sanofi Recent Developments/Updates

Table 85. Pfizer Inc Corporation Information

Table 86. Pfizer Inc Description and Business Overview

Table 87. Pfizer Inc Poly-Myalgia Rheumatica Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Pfizer Inc Poly-Myalgia Rheumatica Treatment Product

Table 89. Pfizer Inc Recent Developments/Updates

Table 90. GSK plc Corporation Information

Table 91. GSK plc Description and Business Overview

Table 92. GSK plc Poly-Myalgia Rheumatica Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. GSK plc Poly-Myalgia Rheumatica Treatment Product

Table 94. GSK plc Recent Developments/Updates

Table 95. Novartis AG Corporation Information

Table 96. Novartis AG Description and Business Overview

Table 97. Novartis AG Poly-Myalgia Rheumatica Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Novartis AG Poly-Myalgia Rheumatica Treatment Product

Table 99. Novartis AG Recent Developments/Updates

Table 100. AstraZeneca Corporation Information

Table 101. AstraZeneca Description and Business Overview

Table 102. AstraZeneca Poly-Myalgia Rheumatica Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. AstraZeneca Poly-Myalgia Rheumatica Treatment Product

Table 104. AstraZeneca Recent Developments/Updates

Table 105. Johnson & Johnson Private Limited Corporation Information

Table 106. Johnson & Johnson Private Limited Description and Business Overview

Table 107. Johnson & Johnson Private Limited Poly-Myalgia Rheumatica Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Johnson & Johnson Private Limited Poly-Myalgia Rheumatica Treatment Product

Table 109. Johnson & Johnson Private Limited Recent Developments/Updates

Table 110. Sun Pharmaceutical Industries Ltd Corporation Information

Table 111. Sun Pharmaceutical Industries Ltd Description and Business Overview

Table 112. Sun Pharmaceutical Industries Ltd Poly-Myalgia Rheumatica Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Sun Pharmaceutical Industries Ltd Poly-Myalgia Rheumatica Treatment Product

Table 114. Sun Pharmaceutical Industries Ltd Recent Developments/Updates

Table 115. Merck & Co., Inc Corporation Information

Table 116. Merck & Co., Inc Description and Business Overview

Table 117. Merck & Co., Inc Poly-Myalgia Rheumatica Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Merck & Co., Inc Poly-Myalgia Rheumatica Treatment Product

Table 119. Merck & Co., Inc Recent Developments/Updates

Table 120. Lilly Corporation Information

Table 121. Lilly Description and Business Overview

Table 122. Lilly Poly-Myalgia Rheumatica Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. Lilly Poly-Myalgia Rheumatica Treatment Product

Table 124. Lilly Recent Developments/Updates

Table 125. Amgen Inc Corporation Information

Table 126. Amgen Inc Description and Business Overview

Table 127. Amgen Inc Poly-Myalgia Rheumatica Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. Amgen Inc Poly-Myalgia Rheumatica Treatment Product

Table 129. Amgen Inc Recent Developments/Updates

Table 130. PuraCap® Pharmaceutical LLC Corporation Information

Table 131. PuraCap® Pharmaceutical LLC Description and Business Overview

Table 132. PuraCap® Pharmaceutical LLC Poly-Myalgia Rheumatica Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. PuraCap® Pharmaceutical LLC Poly-Myalgia Rheumatica Treatment Product

Table 134. PuraCap® Pharmaceutical LLC Recent Developments/Updates

Table 135. Glenmark Pharmaceuticals Limited Corporation Information

Table 136. Glenmark Pharmaceuticals Limited Description and Business Overview

Table 137. Glenmark Pharmaceuticals Limited Poly-Myalgia Rheumatica Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 138. Glenmark Pharmaceuticals Limited Poly-Myalgia Rheumatica Treatment Product

Table 139. Glenmark Pharmaceuticals Limited Recent Developments/Updates

Table 140. Key Raw Materials Lists

Table 141. Raw Materials Key Suppliers Lists

Table 142. Poly-Myalgia Rheumatica Treatment Distributors List

Table 143. Poly-Myalgia Rheumatica Treatment Customers List

Table 144. Poly-Myalgia Rheumatica Treatment Market Trends

Table 145. Poly-Myalgia Rheumatica Treatment Market Drivers

Table 146. Poly-Myalgia Rheumatica Treatment Market Challenges

Table 147. Poly-Myalgia Rheumatica Treatment Market Restraints

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Poly-Myalgia Rheumatica Treatment

Figure 2. Global Poly-Myalgia Rheumatica Treatment Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Poly-Myalgia Rheumatica Treatment Market Share by Type in 2023 & 2030

Figure 4. Glucocorticoid Product Picture

Figure 5. NSAIDs Product Picture

Figure 6. Global Poly-Myalgia Rheumatica Treatment Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Poly-Myalgia Rheumatica Treatment Market Share by Application in 2023 & 2030

Figure 8. Hospital

Figure 9. Specialist Clinic

Figure 10. Global Poly-Myalgia Rheumatica Treatment Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 11. Global Poly-Myalgia Rheumatica Treatment Market Size (2019-2030) & (US$ Million)

Figure 12. Global Poly-Myalgia Rheumatica Treatment Sales (2019-2030) & (K Units)

Figure 13. Global Poly-Myalgia Rheumatica Treatment Average Price (US$/Unit) & (2019-2030)

Figure 14. Poly-Myalgia Rheumatica Treatment Report Years Considered

Figure 15. Poly-Myalgia Rheumatica Treatment Sales Share by Manufacturers in 2023

Figure 16. Global Poly-Myalgia Rheumatica Treatment Revenue Share by Manufacturers in 2023

Figure 17. The Global 5 and 10 Largest Poly-Myalgia Rheumatica Treatment Players: Market Share by Revenue in 2023

Figure 18. Poly-Myalgia Rheumatica Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 19. Global Poly-Myalgia Rheumatica Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 20. North America Poly-Myalgia Rheumatica Treatment Sales Market Share by Country (2019-2030)

Figure 21. North America Poly-Myalgia Rheumatica Treatment Revenue Market Share by Country (2019-2030)

Figure 22. United States Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 23. Canada Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 24. Europe Poly-Myalgia Rheumatica Treatment Sales Market Share by Country (2019-2030)

Figure 25. Europe Poly-Myalgia Rheumatica Treatment Revenue Market Share by Country (2019-2030)

Figure 26. Germany Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. France Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. U.K. Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Italy Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Russia Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Asia Pacific Poly-Myalgia Rheumatica Treatment Sales Market Share by Region (2019-2030)

Figure 32. Asia Pacific Poly-Myalgia Rheumatica Treatment Revenue Market Share by Region (2019-2030)

Figure 33. China Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Japan Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. South Korea Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. India Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Australia Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. China Taiwan Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Southeast Asia Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Latin America Poly-Myalgia Rheumatica Treatment Sales Market Share by Country (2019-2030)

Figure 41. Latin America Poly-Myalgia Rheumatica Treatment Revenue Market Share by Country (2019-2030)

Figure 42. Mexico Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Brazil Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Argentina Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Poly-Myalgia Rheumatica Treatment Sales Market Share by Country (2019-2030)

Figure 46. Middle East & Africa Poly-Myalgia Rheumatica Treatment Revenue Market Share by Country (2019-2030)

Figure 47. Turkey Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Saudi Arabia Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. UAE Poly-Myalgia Rheumatica Treatment Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Global Sales Market Share of Poly-Myalgia Rheumatica Treatment by Type (2019-2030)

Figure 51. Global Revenue Market Share of Poly-Myalgia Rheumatica Treatment by Type (2019-2030)

Figure 52. Global Poly-Myalgia Rheumatica Treatment Price (US$/Unit) by Type (2019-2030)

Figure 53. Global Sales Market Share of Poly-Myalgia Rheumatica Treatment by Application (2019-2030)

Figure 54. Global Revenue Market Share of Poly-Myalgia Rheumatica Treatment by Application (2019-2030)

Figure 55. Global Poly-Myalgia Rheumatica Treatment Price (US$/Unit) by Application (2019-2030)

Figure 56. Poly-Myalgia Rheumatica Treatment Value Chain

Figure 57. Poly-Myalgia Rheumatica Treatment Production Process

Figure 58. Channels of Distribution (Direct Vs Distribution)

Figure 59. Distributors Profiles

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Clotting Factors Ⅷ Market Insights, Forecast to 2030

120 Pages

Type: Report

Code: QYRE-Auto-21S8513

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Rare Genetic Disease Diagnosis Solution - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-17L15214

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Endoscopes for Otology - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-19V14797

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Immunotherapy Drugs for Neuroblastoma - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-39R14639

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions